Fig. 3
From: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM
Cross-validated OPLS-DA scores, second predictive component (tcv[2]), for the GC-TOFMS data of cell supernatants of normal astrocytes (Astro; white bars), ASS-ve cells (SNB19; black bars) and ASS+ve cells (U87; grey bars). ADI-PEG20 treated samples are denoted by stars. The plot clearly shows that the ASS-ve samples are significantly affected by treatment (p < 0,001) while normal cells and ASS1 + ve cells remain largely unaffected